

- The creation of the Nestlé Health Science Company and the Nestlé Institute of Health Sciences is a major strategic move for Nestlé to pioneer a new industry between traditional nutrition and pharma.
- Both entities began operations in 2011 and made a strong start in their quest to develop science-based personalised nutrition to prevent and treat increasingly prevalent health conditions that are placing an unsustainable burden on the world's healthcare systems.
- Nestlé Health Science's aims to develop science-based personalised nutritional solutions in six disease areas.
  - Already strong and growing core HealthCare Nutrition business in acute disease areas of Ageing Medical Care, Critical Care and Surgery, and Paediatric Medical Care.
  - Chronic disease areas being addressed: Gastrointestinal Health, Metabolic Health and Brain Health.



- Nestlé Health Science is the global # 2 healthcare nutrition player, with a strong presence in the US, Europe, Asia and South America.
- Nestlé Health Science's innovations and development will rely on the Nestlé Institute of Health Sciences (NIHS) and the Nestlé R&D network. The NIHS will spearhead world-class biomedical research to better understand health and disease as influenced by genetics, metabolism and environment with the goal of translating this knowledge into personalised science-based nutrition.
- Nestlé Health Science Headquarters: Lutry (Switzerland); around 3'000 employees worldwide.
- Key web links: [www.nestlehealthscience.com](http://www.nestlehealthscience.com) / [www.nestleinstitutehealthsciences.com](http://www.nestleinstitutehealthsciences.com)

### Acquisitions

- **Vitaflor** Growing portfolio of clinical nutritional solutions for metabolic disorders (2010)
- **CM&D Pharma** Developing range of products tailored for patients with kidney disease, inflammatory bowel disease, and colon cancer (2011)
- **Prometheus** Diagnostics and therapeutics in GI and oncology (2011)
- **Vital Foods** Minority stake; specialised in the area of GI conditions (2011)
- **Accera** Minority stake; specialised in neurodegenerative disorders, like Alzheimer's Disease (2012)

